Haining Huang

Haining Huang, Ph.D. has extensive experience in the biopharmaceutical industry, with a focus on drug discovery and development in the field of immuno-oncology. Haining currently serves as the CSO at Cytimm Therapeutics within Sorrento Therapeutics, Inc. Prior to this, they were the VP of Drug Discovery at ACEA Therapeutics, where they built and managed a large molecule drug discovery department and successfully initiated multiple projects. Haining previously held positions at Oxford BioTherapeutics, Sorrento Therapeutics, Inc., Senomyx, Inc., La Jolla Institute for Allergy and Immunology, UCSD, and The Scripps Research Institute, where they contributed to various research projects and made significant contributions in the areas of T cell biology, GPCR research, receptor trafficking, and cancer treatment. Dr. Huang's work has resulted in multiple patents and publications in scientific journals.

Haining Huang, Ph.D. completed a Bachelor of Science degree in Genetics from Fudan University in 1993. Haining then pursued a Master of Science degree in Molecular Biology from Zhejiang University, which they completed in 1996. Subsequently, Haining Huang went on to earn two Ph.D. degrees. Haining first obtained a Ph.D. in Molecular Immunology from Fudan University in 2000. Following that, they completed another Ph.D. in Immunology from Scripps Research in 2000.